跳至主要内容
临床试验/CTRI/2025/09/095165
CTRI/2025/09/095165尚未招募不适用

Evaluation of Safety and Efficacy of Routine Addition of Hydrolyzed Protein Powder to Human Milk Fortifier Enriched Human Milk for Enteral Nutrition Compared to Conventional Human Milk Fortification in Preterm Infants: A Randomized Controlled Trial

Ompriya T P1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2025年10月15日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
50
试验地点
1
主要终点
Safety endpoint is rate of feeding intolerance defined as gastric residual volume greater than 50 percent of the last feed or abdominal distension or emesis requiring withholding of feeds or interruption of feeding for more than 24 hours. Primary efficacy endpoint is rate of postnatal growth failure defined as weight for age z score decline more than 0.8 or weight gain velocity less than 75 percent of expected for postconceptional age assessed at discharge or 34 weeks PMA whichever is later

研究概览

简要总结

Human breast milk especially maternal breast milk is the preferred choice for enteral nutritional support in preterm infants. Human milk based diet compared to formula feeding reduces the risk of mortality necrotizing enterocolitis NEC late onset sepsis retinopathy of prematurity bronchopulmonary dysplasia and duration of hospital stay in preterm infants. Maternal breast milk is superior to donor breast milk feeding in improving long term neurodevelopmental outcomes in preterm neonates. However there is insufficient calories major macronutrients electrolytes minerals and micronutrients in human breast milk maternal or donor to provide adequate nutritional support and to achieve optimal postnatal growth and proportionate growth in well alignment with intra uterine growth in preterm infants. Accordingly the addition of commercially available standard human milk to human breast milk is routinely being used to mitigate the risks of nutritional insufficiency and suboptimal growth in preterm neonates particularly those with very low birth weight and intra uterine growth restricted neonates as they require enhanced nutritional support to promote physical growth and neurodevelopment. Despite standardized fortification the required daily protein intake may not be met due to restrictive fluid regimen insufficient absorption and poor assimilation in preterm infants. Hydrolyzed protein powder which consists of amino acids is hypothesized to enhance protein absorption and reduce the risk of protein deficiency and promote linear growth head growth and proportionate growth without offsetting the feeding tolerance

This study focuses on preterm neonates who are often deprived of adequate protein supplementation as limited research has been conducted in India on optimized protein supplementation strategies. Based on the biological plausibility we speculate that the addition of extensively hydrolyzed protein powder to already fortified human milk with standard HMF fortification will promote short term physical growth parameters without increasing feeding intolerance in preterm infants. Furthermore this approach may support improved long term neurodevelopmental outcomes. The study aims to evaluate the short term efficacy safety and feasibility of this nutritional strategy using protein fortified powders currently available in India.

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
1.00 Day(s) 至 2.00 Day(s)(—)
性别
All

入选标准

  • All criteria must be met Preterm infants born less than 32 weeks of gestation OR birth weight less than 1500 g At least two weeks of hospital stay is expected Receiving a minimum of 100 ml kg of enteral feeds with human milk based diet either DBM or maternal breast milk fortified with multi nutrient HMF to a standard fortification 0.81 kcal 1 ml or 4 g 100 ml or 1 g sachet per 25 ml Consent obtained for parents Chronological or postnatal age greater than 7 days.

排除标准

  • Neonates with Major Congenital anomalies(known or diagnosed) Chromosomal abnormalities/Identifiable genetic syndrome GI surgical procedure/short bowel syndrome/ostomies NPO status: NEC/feeding intolerance/inotrope-dependent shock Potential non-viabiity and clinical instability as determined by the treating physician.

结局指标

主要结局

Safety endpoint is rate of feeding intolerance defined as gastric residual volume greater than 50 percent of the last feed or abdominal distension or emesis requiring withholding of feeds or interruption of feeding for more than 24 hours. Primary efficacy endpoint is rate of postnatal growth failure defined as weight for age z score decline more than 0.8 or weight gain velocity less than 75 percent of expected for postconceptional age assessed at discharge or 34 weeks PMA whichever is later

时间窗: At Baseline and weekly interval at discharge or 34 weeks PMA

次要结局

  • .Secondary outcomes (Safety)(1. Necrotizing Enterocolitis)

研究者

发起方
Ompriya T P
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Ompriya T P

JAWAHARLAL NEHRU MEDICAL COLLEGE ,KLE ACADEMY OF HIGHER EDUCATION AND RESEARCH ,BELAGAVI ,KARNATAKA

研究点 (1)

Loading locations...

相似试验